3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Myeloid
1
Conditions
Breast Neoplasms
7
Prostatic Neoplasms
4
Brain Neoplasms
4
Neoplasms
3
Neoplasm Metastasis
3
Sarcoma
2
Multiple Myeloma
2
Lung Neoplasms
2
Glioma
2
Glioblastoma
2
Gastrointestinal Neoplasms
2
Fatigue
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma, Hepatocellular
2
Weight Loss
1
Uterine Cervical Neoplasms
1
Thrombocytopenia
1
Symptom Management
1
Stomach Neoplasms
1
Splenomegaly
1
Sexual Dysfunction, Physiological
1
Sex Cord-Gonadal Stromal Tumors
1
Sarcoma, Synovial
1
Rectal Neoplasms
1
Peritoneal Neoplasms
1
Pain
1
Ovarian Neoplasms
1
Oligodendroglioma
1
Neuroendocrine Tumors
1
Neoplasms, Germ Cell and Embryonal
1
Interventions
Cyclophosphamide
209
fludarabine phosphate
184
Azacitidine
159
fludarabine
142
Busulfan
138
Tacrolimus
119
Mycophenolic Acid
111
Cytarabine
110
Whole-Body Irradiation
106
Peripheral Blood Stem Cell Transplantation
98
Antilymphocyte Serum
97
Melphalan
90
Filgrastim
87
Cyclosporine
83
Decitabine
82
Methotrexate
79
venetoclax
63
Granulocyte Colony-Stimulating Factor
56
Radiotherapy
49
Stem Cell Transplantation
48
Thiotepa
47
Cord Blood Stem Cell Transplantation
42
Clofarabine
42
thymoglobulin
41
Specimen Handling
35
Etoposide
35
Methylprednisolone
34
Sirolimus
33
Injections
27
Biopsy
26
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Myelodysplastic Syndromes
×
Quality of Life
×
Clear all
NCT07387354
2026-03-16
MDS
Thomas Jefferson University
Phase 1/2
Not yet recruiting
25 enrolled